A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol

被引:13
作者
Allen, Stephen J. [1 ]
Wareham, Kathie [2 ]
Bradley, Caroline [3 ]
Harris, Wyn [4 ]
Dhar, Anjan [3 ]
Brown, Helga [3 ]
Foden, Alwyn [3 ]
Cheung, Way Yee
Gravenor, Michael B.
Plummer, Sue [5 ]
Phillips, Ceri J.
Mack, Dietrich
机构
[1] Swansea Univ, Coll Med, Swansea SA2 8PP, W Glam, Wales
[2] Morriston Hosp, Clin Res Unit, Swansea SA6 6NL, W Glam, Wales
[3] Darlington Mem Hosp, Cty Durham & Darlington NHS Fdn Trust, Durham DL3 6HX, Darlington Coun, England
[4] Abertawe Bro Morgannwg Univ Hosp Board, Baglan SA12 7BR, Port Talbot, England
[5] Obsidian Res Ltd, Port Talbot SA12 7BZ, W Glamorgan, England
关键词
Probiotic; Lactobacilli; Bifidobacteria; Antibiotic; Antibiotic associated diarrhoea; Clostridium difficile diarrhoea; Elderly; Hospital in-patient; DIFFICILE-ASSOCIATED DISEASE; RISK;
D O I
10.1186/1471-2334-12-108
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Antibiotic associated diarrhoea complicates 5-39% of courses of antibiotic treatment. Major risk factors are increased age and admission to hospital. Of particular importance is C. difficile associated diarrhoea which occurs in about 4% of antibiotic courses and may result in severe illness, death and high healthcare costs. The emergence of the more virulent 027 strain of C. difficile has further heightened concerns. Probiotics may prevent antibiotic associated diarrhoea by several mechanisms including colonization resistance through maintaining a healthy gut flora. Methods: This study aims to test the hypothesis that administration of a probiotic comprising two strains of lactobacilli and two strains of bifidobacteria alongside antibiotic treatment prevents antibiotic associated diarrhoea. We have designed a prospective, parallel group trial where people aged 65 years or more admitted to hospital and receiving one or more antibiotics are randomly allocated to receive either one capsule of the probiotic or a matching placebo daily for 21 days. The primary outcomes are the frequency of antibiotic associated and C. difficile diarrhoea during 8-12 weeks follow-up. To directly inform routine clinical practice, we will recruit a sufficient number of patients to demonstrate a 50% reduction in the frequency of C. difficile diarrhoea with a power of 80%. To maximize the generalizability of our findings and in view of the well-established safety record of probiotics, we will recruit a broad range of medical and surgical in-patients from two different health regions within the UK. Discussion: Antibiotic associated diarrhoea constitutes a significant health burden. In particular, current measures to prevent and control C. difficile diarrhoea are expensive and disrupt clinical care. This trial may have considerable significance for the prevention of antibiotic associated diarrhoea in hospitals.
引用
收藏
页数:8
相关论文
共 33 条
  • [1] Allen SJ, EUROPEAN GA IN PRESS
  • [2] [Anonymous], CLOSTR DIFF INF DEAL
  • [3] Antibiotic-associated diarrhea
    Bartlett, JG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (05) : 334 - 339
  • [4] Clostridium difficile infection in Europe: a hospital-based survey
    Bauer, Martijn P.
    Notermans, Daan W.
    van Benthem, Birgit H. B.
    Brazier, Jon S.
    Wilcox, Mark H.
    Rupnik, Maja
    Monnet, Dominique L.
    van Dissel, Jaap T.
    Kuijper, Ed J.
    [J]. LANCET, 2011, 377 (9759) : 63 - 73
  • [5] Treatment and prevention of antibiotic associated diarrhea
    Bergogne-Bérézin, E
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (04) : 521 - 526
  • [6] Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial
    Besselink, Marc G. H.
    van Santvoort, Hjalmar C.
    Buskens, Erik
    Boermeester, Marja A.
    van Goor, Harry
    Timmerman, Harro M.
    Nieuwenhuijs, Vincent B.
    Bollen, Thomas L.
    van Ramshorst, Bert
    Witteman, Ben J. M.
    Rosman, Camiel
    Ploeg, Rutger J.
    Brink, Menno A.
    Schaapherder, Alexander F. M.
    Dejong, Cornelis H. C.
    Wahab, Peter J.
    van Laarhoven, Cees J. H. M.
    van der Harst, Erwin
    van Eijck, Casper H. J.
    Cuesta, Miguel A.
    Akkermans, Louis M. A.
    Gooszen, Hein G.
    [J]. LANCET, 2008, 371 (9613) : 651 - 659
  • [7] Brookes S T, 2001, Health Technol Assess, V5, P1
  • [8] The emergence of 'hypervirulence' in Clostridium difficile
    Cartman, Stephen T.
    Heap, John T.
    Kuehne, Sarah A.
    Cockayne, Alan
    Minton, Nigel P.
    [J]. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2010, 300 (06) : 387 - 395
  • [9] Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy
    Dial, Sandra
    Delaney, J. A. Chris
    Schneider, Verena
    Suissa, Samy
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 175 (07) : 745 - 748
  • [10] The Ecology and Pathobiology of Clostridium difficile Infections: An Interdisciplinary Challenge
    Dubberke, E. R.
    Haslam, D. B.
    Lanzas, C.
    Bobo, L. D.
    Burnham, C. -A. D.
    Groehn, Y. T.
    Tarr, P. I.
    [J]. ZOONOSES AND PUBLIC HEALTH, 2011, 58 (01) : 4 - 20